Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 3817 - 3824 of 12141 results

Bioethics in a Pandemic: Vaccine Research and Clinical Trials
September 16, 2020| Blog| Viewpoint

How Much Is a Startup Worth? For Biotech Companies, the Answer Is Rarely Public
September 16, 2020| News

Trump Signs Executive Orders Aimed at Tying Domestic Drug Prices to Foreign Prices
September 15, 2020| Blog| Viewpoint

Fact-Specific Inquiry: Deciding Between Trade Secret and Patent Protection
September 15, 2020| Blog| Viewpoint

SEC Adopts Amendments to Disclosures of Business (Item 101), Legal Proceedings (Item 103), and Risk Factors (Item 105) Under Regulation S-K
September 14, 2020| Advisory| Viewpoint

Patent Application Declarations for Unavailable or Uncooperative Inventors
September 14, 2020| Blog| Viewpoint

DOJ to IEEE: Yes, Injunctive Relief Should Be Available for SEPs, and Stop Saying Otherwise
September 14, 2020| Blog| Viewpoint

How Some Attys Are Ditching BigLaw For Public Interest Work
September 14, 2020| News
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts

Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|

Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
